ADDF’s Fillit On FDA’s Tough Aducanumab Decision, Advances In Alzheimer’s
New Blood Test Should Aid Drug Trials, Symptomatic Treatments Advancing
The pending US FDA decision on Biogen’s drug overshadows progress in Alzheimer’s diagnosis, symptomatic treatments and the need to keep studying anti-tau therapies after Roche’s setback.
